Risk of colon cancer recurrence in relation to diabetes
- 161 Downloads
To describe the association between diabetes and colon cancer recurrence.
We conducted a cohort study at two integrated health care delivery systems in the United States. Using tumor registry data, we identified patients aged ≥ 18 years when diagnosed with stage I–IIIA adenocarcinomas of the colon during 1995–2014. Pre-existing diabetes was ascertained via diagnosis codes. Medical records were reviewed for eligibility and to abstract recurrence and covariate information. Recurrence was ascertained beginning 90 days after the end of colon cancer treatment (i.e., cohort entry). Recurrence of any cancer or a new primary cancer at any site was a secondary outcome. We used multivariable Cox proportional hazards models to estimate hazard ratios (HR) and 95% confidence intervals (CIs) for the associations between diabetes at cohort entry and study outcomes.
Among the 1,923 eligible patients, 393 (16.7%) had diabetes at cohort entry. Diabetes was not associated with recurrence (HR 0.87; 95% CI 0.56–1.33) or with any subsequent cancer (HR 1.09; 95% CI 0.85–1.40). When the definition of recurrence included second primary colorectal cancer, risk was non-significantly higher in patients with diabetes than without diabetes.
The risk of colon cancer recurrence appears to be similar in patients with and without diabetes at diagnosis.
Future studies should evaluate the association between diabetes and colorectal cancer outcomes, especially second primary colon cancers, in larger populations.
KeywordsColon cancer Recurrence Diabetes Survivorship
We would like to thank Dr. Elizabeth Trice Loggers for assistance with designing the medical record abstraction instrument and providing clinical input, and Lee Barr, Kate Burniece, and Angela Plata for reviewing medical records. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers R01CA172073 (Chubak) and R50CA211115 (Bowles). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The collection of cancer incidence data used in this study was supported by the Cancer Surveillance System of the Fred Hutchinson Cancer Research Center, which is funded by Contract No. N01-CN-67009 and N01-PC-35142 from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute with additional support from the Fred Hutchinson Cancer Research Center and the State of Washington. Funders did not participate in the design, data collection, manuscript drafting, or decision to submit the manuscript for publication.
Monica Fujii reports receiving funding from a research contracts awarded to Kaiser Permanente Washington Health Research Institute from Allergan, BioDelivery Sciences, Collegium, Daiichi Sankyo, Depomed, Egalet, Endo, Janssen, Mallinckrodt, Pernix, Pfizer, Purdue, and West-Ward. Denise Boudreau reports receiving funding from research contracts awarded to Kaiser Permanente Washington Health Research Institute from Allergan, BioDelivery Sciences, Collegium, Daiichi Sankyo, Depomed, Egalet, Endo, Janssen, Mallinckrodt, Pernix, Pfizer, Purdue, and West-Ward. Onchee Yu reports receiving funding from a research grant awarded to the Kaiser Permanente Washington Health Research Institute from Bayer.
Compliance with ethical standards
For this type of study, formal consent is not required.
Research involving animals
This article does not contain any studies with animals performed by any of the authors.
- 1.Bullard KM, Cowie CC, Lessem SE, Saydah SH, Menke A, Geiss LS, Orchard TJ, Rolka DB, Imperatore G (2018) Prevalence of diagnosed diabetes in adults by diabetes type—United States, 2016. MMWR Morb Mortal Wkly Rep 67(12):359–361. https://doi.org/10.15585/mmwr.mm6712a2 CrossRefPubMedPubMedCentralGoogle Scholar
- 2.Cossor FI, Adams-Campbell LL, Chlebowski RT, Gunter MJ, Johnson K, Martell RE, McTiernan A, Simon MS, Rohan T, Wallace RB, Paulus JK (2013) Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. Cancer Epidemiol 37(5):742–749. https://doi.org/10.1016/j.canep.2013.04.015 CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Dehal AN, Newton CC, Jacobs EJ, Patel AV, Gapstur SM, Campbell PT (2012) Impact of diabetes mellitus and insulin use on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol 30(1):53–59. https://doi.org/10.1200/jco.2011.38.0303 CrossRefPubMedGoogle Scholar
- 4.Garrett CR, Hassabo HM, Bhadkamkar NA, Wen S, Baladandayuthapani V, Kee BK, Eng C, Hassan MM (2012) Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer 106(8):1374–1378. https://doi.org/10.1038/bjc.2012.71 CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Singh PP, Shi Q, Foster NR, Grothey A, Nair SG, Chan E, Shields AF, Goldberg RM, Gill S, Kahlenberg MS, Sinicrope FA, Sargent DJ, Alberts SR (2016) Relationship between metformin use and recurrence and survival in patients with resected stage iii colon cancer receiving adjuvant chemotherapy: results from North Central Cancer Treatment Group N0147 (Alliance). Oncologist 21(12):1509–1521. https://doi.org/10.1634/theoncologist.2016-0153 CrossRefPubMedPubMedCentralGoogle Scholar
- 6.González N, Prieto I, del Puerto-Nevado L, Portal-Nuñez S, Ardura JA, Corton M, Fernández-Fernández B, Aguilera O, Gomez-Guerrero C, Mas S, Moreno JA, Ruiz-Ortega M, Sanz AB, Sanchez-Niño MD, Rojo F, Vivanco F, Esbrit P, Ayuso C, Alvarez-Llamas G, Egido J, García-Foncillas J, Ortiz A, Consortium DCC (2017) 2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications. Oncotarget 8(11):18456–18485. https://doi.org/10.18632/oncotarget.14472 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njolstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J, Emerging Risk Factors C (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364(9):829–841. https://doi.org/10.1056/NEJMoa1008862 CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Feng J, Zhou X, Mao W (2011) Prognostic analysis of colorectal cancer patients with diabetes mellitus in China—the experience of a single institution. Adv Clin Exp Med 20(4):473–480Google Scholar
- 27.Jeon JY, Jeong DH, Park MG, Lee JW, Chu SH, Park JH, Lee MK, Sato K, Ligibel JA, Meyerhardt JA, Kim NK (2013) Impact of diabetes on oncologic outcome of colorectal cancer patients: colon vs. rectal cancer. PLoS ONE 8(2):e55196. https://doi.org/10.1371/journal.pone.0055196 CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Bae S, Wong HL, Tie J, Desai J, Field K, Kosmider S, Fourlanos S, Jones I, Skinner I, Gibbs P (2015) Impact of diabetes status and medication on presentation, treatment, and outcome of stage II colon cancer patients. J Cancer Epidemiol 2015:189132. https://doi.org/10.1155/2015/189132 CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Chubak J, Ziebell R, Greenlee RT, Honda S, Hornbrook MC, Epstein M, Nekhlyudov L, Pawloski PA, Ritzwoller DP, Ghai NR, Feigelson HS, Clancy HA, Doria-Rose VP, Kushi LH (2016) The Cancer Research Network: a platform for epidemiologic and health services research on cancer prevention, care, and outcomes in large, stable populations. Cancer Causes Control 27(11):1315–1323. https://doi.org/10.1007/s10552-016-0808-4 CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Bella F, Minicozzi P, Giacomin A, Crocetti E, Federico M, Ponz de Leon M, Fusco M, Tumino R, Mangone L, Giuliani O, Budroni M, Sant M (2013) Impact of diabetes on overall and cancer-specific mortality in colorectal cancer patients. J Cancer Res Clin Oncol 139(8):1303–1310. https://doi.org/10.1007/s00432-013-1439-8 CrossRefPubMedGoogle Scholar